ROOT, Switzerland, 14 August 2024 â Novocure (NASDAQ: NVCR) today announced its participation in the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer (WCLC), taking place from 7-10 September 2024 in San Diego, California. Novocure will be actively involved in presentations, symposia, and poster sessions exploring the use of Tumor Treating Fields (TTFields) therapy in the treatment of lung cancer. This includes a new post-hoc analysis of data from the LUNAR trial for metastatic non-small cell lung cancer (NSCLC).
"We are excited to share these promising new analyses with the lung cancer community," stated Nicolas Leupin, MD, Novocure's Chief Medical Officer. "TTFields therapy offers significant potential for the treatment of this prevalent disease. With multiple regulatory reviews currently underway, there is no better time to examine the potential benefits of TTFields in the treatment of NSCLC."
The new post-hoc analysis investigated survival data from the phase 3 LUNAR clinical trial, alongside data from a simulation study, to evaluate the impact of body mass index (BMI) on overall survival (OS) and the feasibility of delivering TTFields at a therapeutic intensity to patients with varying BMIs. The investigators found no difference in OS benefit between patients with a BMI less than 25 kg/m<sup>2 </sup>compared to those with a BMI greater than 25 kg/m<sup>2</sup>. Furthermore, data from the simulation-based study suggests that TTFields can be delivered to the lungs at a therapeutic dose, resulting in a corresponding clinical benefit for patients across a range of BMIs.
The LUNAR trial aimed to assess the effectiveness of TTFields therapy in conjunction with standard systemic therapies for metastatic NSCLC, following disease progression after platinum-based therapy. The trial successfully met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in OS for patients treated with TTFields and standard systemic therapies. Notably, a pronounced increase in OS was also observed for patients assigned to receive a physician's choice immune checkpoint inhibitor alongside TTFields. Novocure has submitted these data to regulatory agencies for approval and anticipates initiating patient treatment in late 2024.
Novocure's presence at the 2024 WCLC will encompass:
Sunset Seminar: Women in Thoracic Oncology, hosted by Women Leaders in Oncology (WLO), sponsored by Novocure, on 8 September 2024, at 6:00 p.m. UTC-7
Impact of BMI on TTFields in Patients with mNSCLC: Post-hoc Analysis from the Phase 3 LUNAR Study and Simulation Model Data. Poster P1.098B.04 displayed in the Exhibit Hall on 8 September 2024, at 12:00 p.m. UTC-7
About Tumor Treating Fields Therapy
Tumor Treating Fields (TTFields) are electric fields that exert physical forces to kill cancer cells through a variety of mechanisms. TTFields do not significantly affect healthy cells due to their different properties (including division rate, morphology, and electrical properties) compared to cancer cells. These multiple, distinct mechanisms work together to target and kill cancer cells. As a result of these multimechanistic actions, TTFields therapy can be combined with other cancer treatment modalities in approved indications, demonstrating enhanced effects across solid tumor types when used with chemotherapy, radiotherapy, immune checkpoint inhibition, or targeted therapies in preclinical models. TTFields therapy offers clinical versatility with the potential to address treatment challenges across a range of solid tumours. For further information about Tumor Treating Fields therapy and its multifaceted effect on cancer cells, visit tumortreatingfields.com.
About LUNAR
The LUNAR trial evaluated the safety and efficacy of TTFields therapy combined with either an immune checkpoint inhibitor (ICI) or docetaxel for the treatment of patients diagnosed with metastatic NSCLC following progression after platinum-based therapy. Patients randomly assigned to receive TTFields therapy in addition to standard therapies (n=137) exhibited a median overall survival (OS) of 13.2 months compared to 9.9 months for patients receiving standard therapies alone (n=139). Patients randomly assigned to receive TTFields therapy and a physician's choice ICI (n=66) demonstrated a median OS of 18.5 months versus a median OS of 10.8 months in patients treated with an ICI alone (n=68; HR=0.63; P=0.03). Patients randomly assigned to receive TTFields therapy and docetaxel (n=71) showed a positive survival trend with a median OS of 11.1 months compared to 8.7 months in patients treated with docetaxel alone (n=71). TTFields therapy was well-tolerated with no added systemic toxicities and few grade 3 (no grade 4 or 5) device-related adverse events.
About Novocure
Novocure is a global oncology company dedicated to extending survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical studies investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.
Headquartered in Root, Switzerland, and with a growing global footprint, Novocure has regional operating centres in Portsmouth, New Hampshire, and Tokyo, as well as a research centre in Haifa, Israel. For more information about the company, please visit Novocure.com and follow @Novocure on LinkedIn and Twitter.
Forward-Looking Statements
In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocureâs current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical study progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Novocureâs performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 22, 2024, and subsequent filings with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.
Contacts
INVESTORS:
Ingrid Goldberg
investorinfo@novocure.com
MEDIA:
Catherine Falcetti
media@novocure.com